REFERENCES

  1. RYBELSUS® (semaglutide tablets) Product Monograph. Novo Nordisk Canada Inc., 2020.

  2. Rosenstock J, et al. Effect of additional oral semaglutide versus sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466-1480.
    A 78-week, double-blind trial to compare the efficacy and safety of RYBELSUS® vs. Januvia®. A total of 1864 patients with type 2 diabetes were randomized to receive RYBELSUS® 3 mg (n=466), RYBELSUS® 7 mg (n = 465), RYBELSUS® 14 mg (n = 465), or sitagliptin 100 mg (n = 467) once daily, all in combination with metformin alone or metformin and sulfonylurea. The primary endpoint was change in A1C from baseline to week 26.

  3. Rodbard HW, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42(12):2272-2281.
    A 52-week, open-label trial (26-week primary endpoint) to compare the efficacy and safety of RYBELSUS® vs. Jardiance®. A total of 821 patients with type 2 diabetes were randomized to receive RYBELSUS® 14 mg (n = 411) once daily or empagliflozin 25 mg (n = 410) once daily, both in combination with metformin.

  4. Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): A randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.
    A 52-week, double-blind trial to compare the efficacy and safety of RYBELSUS® vs. Victoza®. A total of 711 patients with type 2 diabetes were randomized to receive RYBELSUS® 14 mg once daily (n = 285), liraglutide 1.8 mg subcutaneous injection (n = 284) once daily, or placebo (n = 142) once daily, all in combination with metformin or metformin and an SGLT2 inhibitor. The primary endpoint was change in A1C from baseline to week 26.